A publication dated July 16, 2026 reports on a Phase III, open-label, randomized clinical trial examining epidermal growth factor combined with growth hormone releasing hexapeptide, also known as GHRP-6, in patients with acute ischemic stroke. The study appeared in the Journal of Clinical Neuroscience, the official journal of the Neurosurgical Society of Australasia.
The title of the publication is "Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke." The listing identifies the trial as Phase III and open-label in design, with randomization noted as part of its methodology.
No outcome data, efficacy claims, or safety findings are included in the available event information. GHRP-6 remains classified as an unapproved compound used in research settings. This brief reflects only the publication record as listed and does not represent an evaluation of the trial's results.
Readers seeking general background on GHRP-6 can consult the compound overview for additional context.